Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

1 Jul 2013
by Working Group

Posted in Action, TB Drug Development, TB News

TAG Releases 2013 Pipeline Report

Click here to access full report

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

24 Jun 2013
by Working Group

Posted in Announcements, Early Drug Development, Events

“Targets for Tomorrow” Workshop at GRC in Italy July 2013

tb-review-4.10-lipsitch-feature

We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy.

TB R&D Update: Vitamin C Kills Tuberculosis in vitro

ncomms2898-i1

This week we highlight a study out of Dr. William Jacobs, Jr.’s lab showing that “vitamin C, a compound known to drive the Fenton reaction, sterilizes cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis.” Additional links to other news and articles related to TB R&D are included.

Immunotherapeutic Vaccines, TB and China: Interview with Dr. Douglas Lowrie

thumb206-lowrie

This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.

29 Aug 2012

Live Streaming of Demystifying Pyrazinamide Workshop–September 5 & 6

Pyrazinamide_Structure

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available.

15 Aug 2012

2012 WGND Annual Meeting is Nov 14 in Kuala Lumpur

2010 Annual Meeting

We will have our 2012 Annual Meeting in Kuala, Lumpur on Wednesday, November 14 at the Impiana KLCC Hotel from 13:00 to 17:30. The meeting will be held in conjunction with the 43rd Union World Conference on Lung Health.

7 Jun 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB

Delamanid (OPC-67683)

This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.

25 May 2012

TB R&D Weekly Update: Expanding Our Options for TB Treatment

tb-e1332174457196

For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.

1 May 2012
by Working Group

Posted in Announcements, Events, TB News

Watch Video from the World TB Day Congressional Briefing

congress-hearing

A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Links to video included.

11 Apr 2012

TB R&D Update: Strategies for Early and Late Stage Drug Development

9.cover

This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing. Additional links to TB R&D publications and news are included.